Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Prepaid Assets (2020 - 2025)

Arcutis Biotherapeutics has reported Prepaid Assets over the past 6 years, most recently at $21.1 million for Q4 2025.

  • Quarterly results put Prepaid Assets at $21.1 million for Q4 2025, up 7.24% from a year ago — trailing twelve months through Dec 2025 was $21.1 million (up 7.24% YoY), and the annual figure for FY2025 was $21.1 million, up 7.24%.
  • Prepaid Assets for Q4 2025 was $21.1 million at Arcutis Biotherapeutics, up from $20.3 million in the prior quarter.
  • Over the last five years, Prepaid Assets for ARQT hit a ceiling of $22.9 million in Q1 2025 and a floor of $10.6 million in Q4 2022.
  • Median Prepaid Assets over the past 5 years was $15.4 million (2021), compared with a mean of $16.2 million.
  • Biggest five-year swings in Prepaid Assets: soared 327.86% in 2021 and later decreased 27.8% in 2022.
  • Arcutis Biotherapeutics' Prepaid Assets stood at $14.2 million in 2021, then dropped by 25.13% to $10.6 million in 2022, then soared by 76.27% to $18.7 million in 2023, then increased by 5.09% to $19.7 million in 2024, then increased by 7.24% to $21.1 million in 2025.
  • The last three reported values for Prepaid Assets were $21.1 million (Q4 2025), $20.3 million (Q3 2025), and $18.6 million (Q2 2025) per Business Quant data.